COURSES TAUGHT

  • Cancer Pathology
  • Cancer Pathology
  • Clinical Genetics
  • Clinical Genetics
  • Genetic Engineering
  • Genetic Engineering
  • Genetic Engineering
  • Molecular Biology
  • Molecular Biology
  • Molecular Biology

ACADEMIC RANKS

Rank University Country Date
Professor January 2007

QUALIFICATION

Degree Institute Specialization Country Date
Phd Liverpool University, UK Biochemistry January 1997
Masters Degree Liverpool University, UK Biochemistry January 1993
Bachelors Degree Alexandria University, Egypt Biochemistry January 1981

WORK EXPERIENCE

Job Title Institute Country Time Period
Professor of Cancer Pathology and Dean of Faculty of Pharmacy Faculty of Pharmacy, Al-Ahliyya Amman University September 2019 - January Present
Head of Collaborative Targeted Therapeutics & Diagnostics University of Bradford January 2016 - January 2019
Deputy Director of Institute of Cancer Therapeutics University of Bradford January 2014 - January Present
Anniversary Professor in Molecular Pathology and Cancer Therapeutics University of Bradford January 2014 - January 2014
Professor in Molecular Oncology Centre of Cancer Research and Cell Biology Queens University Belfast January 2012 - January 2014
Senior Lecturer in Molecular Oncology Queens University Belfast January 2008 - January 2012
Lecturer in Molecular Oncology, Centre of Cancer Research and Cell Biology Queens University Belfast January 2002 - January 2008
Postdoctoral Research Associate, School of Biological Sciences University of Liverpool January 1997 - January 2002
Research Assistant, School of Biological Sciences University of Liverpool January 1994 - January 1997
Consultant Clinical Biochemist Alexandria University Hospital, Egypt January 1993 - January 1994
Registrar Clinical Biochemist King Khalid Hospital, Najran, Saudi Arabia January 1987 - January 1992
Clinical Biochemist Alexandria University Hospital, Egypt January 1981 - January 1986

RESEARCH INTERESTS

  • Cancer research

RESEARCHES & PUBLICATIONS

  • Mohamed El - Tanani, Paul McCarron, Ahmed Faheem (2019) Anti-Invasive and Anti-Proliferative Effects of shRNA-Loaded Poly(Lactide-Co-Glycolide) Nanoparticles Following RAN Silencing in MDA-MB231 Breast Cancer Cells. Pharmaceutical Research, 36: 26
  • Yusuf A Haggag, Kyle B Matchett, Robert A Falconer, Mohammad Isreb, Jason Jones, Ahmed Faheem, Paul McCarron, Mohamed El-Tanani (2019) Novel ran-RCC1 inhibitory peptide-loaded nanoparticles have anti-cancer efficacy in vitro and in vivo. Cancers, 11(2): 222
  • Samuel M Girgis, Amal A Elkordy, Mohamed El-Tanani, Ahmed M Faheem (2019) A novel biodegradable system based on poly (lactic-'co'-glycolic acid) nanoparticles for delivery of a novel anticancer peptide. British Journal of Pharmacy, 4(1): S8
  • Samuel M Girgis, Amal A Elkordy, Mohamed El-Tanani, Ahmed M Faheem (2019) A novel microfluidic assembly of a biodegradable nanostructures designed for site specific delivery of an anticancer peptide. British Journal of Pharmacy, 4(1); s10
  • EL-Habib Dakir, Adam Pickard, Kirtiman Srivastava, Cian M McCrudden, Stephane R Gross, Stephen Lloyd, Shu-Dong Zhang, Andriana Margariti, Richard Morgan, Philip S Rudland, Mohamed El-Tanani (2018) The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer. Oncotarget, 9(79)
  • Dalia H Abdelkader, Murtaza M Tambuwala, Christopher A Mitchell, Mohamed A Osman, Sanaa A El-Gizawy, Ahmed M Faheem, Mohamed El-Tanani, Paul A McCarron (2018) Enhanced cutaneous wound healing in rats following topical delivery of insulin-loaded nanoparticles embedded in poly (vinyl alcohol)-borate hydrogels. Drug delivery and translational research, 8(5): 1053-1065
  • Raed A Alharbi, Hardev S Pandha, Guy R Simpson, Ruth Pettengell, Krzysztof Poterlowicz, Alexander Thompson, Kevin Harrington, Mohamed El-Tanani, Richard Morgan (2017) Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. Oncotarget, 8(52)
  • Ka Kui Chan, Kyle B Matchett, Jonathan A Coulter, Hiu-Fung Yuen, Cian M McCrudden, Shu-Dong Zhang, Gareth W Irwin, Matthew A Davidson, Thomas Rülicke, Sophie Schober, Ludger Hengst, Heidelinde Jaekel, Angela Platt-Higgins, Philip S Rudland, Ken I Mills, Perry Maxwell, Mohamed El-Tanani, Terence R Lappin (2017) Erythropoietin drives breast cancer progression by activation of its receptor EPOR. Oncotarget, 8(24)
  • Richard Morgan, Mohamed El-Tanani, Keith D Hunter, Kevin J Harrington, Hardev S Pandha (2017) Targeting HOX/PBX dimers in cancer. Oncotarget, 8(19)
  • Yusuf A Haggag, Kyle B Matchett, El-Habib Dakir, Paul Buchanan, Mohammed A Osman, Sanaa A Elgizawy, Mohamed El-Tanani, Ahmed M Faheem, Paul A McCarron (2017) Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells. International journal of pharmaceutics, 521(1-2): 40-53
  • ELH Dakir, M El-Tanani, NM Dakir (2017) EGFR-An Evolving Cancer Target. Cancer Biol Ther Oncol, 1(1)
  • Richard Morgan, R Ankrah, S El-Tanani, PM Loadman, L Pattterson, PS Rudland, Mohamed El-Tanani (2017) Wnt Signaling as a Therapeutic Target in Cancer and Metastasis. ,
  • Janet PC Wong, Ran Wei, Peng Lyu, Olivia LH Tong, Shu Dong Zhang, Qing Wen, Hiu Fung Yuen, Mohamed El-Tanani, Hang Fai Kwok (2017) Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer. International journal of biological sciences, 13(11);1373
  • Hiu-Fung Yuen, Ka-Kui Chan, Angela Platt-Higgins, EL-Habib Dakir, Kyle B Matchett, Yusuf Ahmed Haggag, Puthen V Jithesh, Tanwir Habib, Ahmed Faheem, Fennell A Dean, Richard Morgan, Philip S Rudland, Mohamed El-Tanani (2016) Ran GTPase promotes cancer progression via Met receptor-mediated downstream signaling. Oncotarget, 7(46)

CONFERENCES & WORKSHOPS

Conference Title Type of Participation Location Date
International Summit on Healthcare, Pharmacy & Industrial Revolution Paper/Poster AND Participate in the organization of Conference November 2019
Conference on Oncology and Cancer Therapy Paper/Poster AND Participate in the organization of Conference February 2019
Annual NCRI Cancer Conference Paper/Poster AND Participate in the organization of Conference November 2018
BioFIT Paper/Poster AND Participate in the organization of Conference December 2018
Oncology Strategy meeting Paper/Poster AND Participate in the organization of Conference November 2017
Oncology Strategy meeting Paper/Poster AND Participate in the organization of Conference October 2017
In Vitro Diagnostics: Oncology and Infectious Diseases Conference Paper/Poster AND Participate in the organization of Conference October 2017
Oncology Strategy meeting Paper/Poster AND Participate in the organization of Conference January 2017
Takeda meeting Paper/Poster AND Participate in the organization of Conference September 2016

CONSULTING & TRAINING COURSES

Title Location Date

THESIS SUPERVISION

Title Location Date
Investigation of the Inhibitory Effect of a Novel MELT-2017 Molecule on Ran-GTPase inTriple Negative Breast Cancer AAU 2020
A Novel MELT 2015 may supress tumour growth and prevent triple negative breast cancer invasion in model system through dysregulation of Ran-GTPase AAU 2020

AWARDS AND SCHOLARSHIP

Title Location Date